Critical Questions in Choosing EGFR-Targeted Therapies for NSCLC - Episode 1

Brief Overview of the Treatment Landscape of First-Line EGFRm NSCLC

,

Panelists discuss how the first-line treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC) primarily includes EGFR tyrosine kinase inhibitors, with osimertinib as the preferred monotherapy due to its efficacy and central nervous system penetration. Balancing efficacy and safety remain challenging, particularly regarding resistance and adverse effects. Although osimertinib monotherapy is widely used, combination strategies (eg, chemotherapy or antiangiogenic agents) are being explored to enhance outcomes. Treatment decisions are guided by mutation type, patient factors, and emerging clinical data.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Brief Overview of the Treatment Landscape of First-Line EGFRm NSCLC
    EP. 2: FLAURA, FLAURA2, and MARIPOSA: Key Takeaways to Impact First-Line Treatment Approach
    EP. 3: Clinical Factors to Consider When Choosing a Treatment Strategy
    EP. 4: Treatment Strategies to Manage AEs in EGFRm NSCLC

    Video content above is prompted by the following:

    • Please provide a brief overview of the treatment landscape of first-line treatment for patients with EGFR-mutated NSCLC.
    • What challenges have you faced in balancing efficacy and safety in EGFR-targeted therapies?
    • Currently, what guides your first-line treatment decisions for patients with EGFR-mutated NSCLC? Are you using osimertinib monotherapy or combination approaches?
    x